Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

BACKGROUND: Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:PLoS One
Autores principales: Diessner, Joachim, Wischnewsky, Manfred, Blettner, Maria, Häusler, Sebastian, Janni, Wolfgang, Kreienberg, Rolf, Stein, Roland, Stüber, Tanja, Schwentner, Lukas, Bartmann, Catharina, Wöckel, Achim
Formato: Artigo
Lenguaje:Inglês
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5167411/
https://ncbi.nlm.nih.gov/pubmed/27992550
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0168730
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares